

## Ajinomoto Bio-Pharma Services expands India facility

14 August 2020 | News

**With the addition of a new production facility in Visakhapatnam**



US based Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a major expansion of small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India.

Construction of the 8,500 square meter facility began at the end of July 2020 and is expected to be completed mid-2022.

To meet the current and future needs of customers, the new small molecule manufacturing facility doubles the production capacity at the site to 310 m<sup>3</sup> for active pharmaceutical ingredients (API) and intermediates and has dedicated equipment to manage OEB 4 high potency ingredients.

Further, the site has completed renovations on existing laboratory space to support additional R&D activities. It is estimated that the expansion will create at least 60 new jobs at the site.

The US FDA approved Ajinomoto Bio-Pharma Services India manufacturing site, which was designed, constructed and is managed based on the Aji Bio-Pharma Belgian sites' GMP operating standards and quality systems, has successfully supported a number of the world's leading biopharmaceutical companies since its formation in 2011 and continues to win awards for sustainability and quality standards.